Panbela Therapeutics, Inc.
If you purchased Panbela Therapeutics, Inc. securities and would like to join the action, please click "Join This Action" below.
PBLA STOCK INVESTIGATION: HALPER SADEH LLP IS INVESTIGATING WHETHER THE MERGER OF PANBELA THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS
February 22, 2022.
New York, New York—Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Panbela Therapeutics, Inc. (NASDAQ: PBLA) and Cancer Prevention Pharmaceuticals, Inc. is fair to Panbela shareholders.
The investigation concerns whether Panbela and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Panbela shareholders; and (2) disclose all material information necessary for Panbela shareholders to adequately assess and value the merger consideration. On behalf of Panbela shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.